Pamela J Sung

9PUBLICATIONS
36CO-AUTHORS
Haematological tumoursPredictive and prognostic markersAcceleratorsMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|May 30, 2026
Management and risk mitigation strategies for FLT3-ITD+ acute myeloid leukemia: clinical utilization of quizartinib.

|Jul 09, 2025
Chemoresistance of TP53 mutant acute myeloid leukemia requires the mevalonate byproduct, geranylgeranyl pyrophosphate, for induction of an adaptive stress response.

Sarah J Skuli, A'ishah Bakayoko, Marisa Kruidenier

|Dec 27, 2024
Significance of cycle 1 bone marrow biopsy in predicting outcomes and toxicities of venetoclax-based therapy for myeloid malignancies.

Jeffrey Baron, Daniel Appiah, Mark G Faber

|May 09, 2024
PIKing the right target in AML.

Pamela J Sung

|Jan 05, 2024
FLT3 tyrosine kinase inhibition modulates PRC2 and promotes differentiation in acute myeloid leukemia.

Pamela J Sung, Murugan Selvam, Simone S Riedel

|Aug 21, 2023
LNS8801 inhibits Acute Myeloid Leukemia by Inducing the Production of Reactive Oxygen Species and Activating the Endoplasmic Reticulum Stress Pathway.

Inyoung Lee, Miriam Doepner, Jillian Weissenrieder

Pageof 2

Frequent Collaborators

3 joint publications

Martin P Carroll

2 joint publications

Jeffrey Baron

1 joint publications

Fangxue Yan

1 joint publications

Jinyang Li